ArticleImmunity2020
Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.
Article in Immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05683353 (Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors and Discovery of Potential Drug Targets), which is not on this map. Cited by 684 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors and Discovery of Potential Drug Targets
Who cites it
684 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature.Frontiers in immunology · 2023Pooled it
- Immunogenicity Characterization of COVID-19 Vaccines: A Systematic Review and Meta-analysis.Revista da Sociedade Brasileira de Medicina Tropical · 2023Pooled it
- The prevalence of adaptive immunity to COVID-19 and reinfection after recovery - a comprehensive systematic review and meta-analysis.Pathogens and global health · 2022Pooled it
- Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients.Haematologica · 2023Trial
- SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests.Scientific reports · 2022Trial
- Broad cross-T cell immunity between emerging SARS-CoV-2 serotypes waved by spike-signature mutations.Emerging microbes & infections · 2026Article
- SARS-CoV-2 Point-of-Care Testing Modalities: Integrating Molecular, Immunological, Biosensor, and AI Approaches.Diagnostics (Basel, Switzerland) · 2026Review
- Deciphering immune features and cellular heterogeneity in PRRSV infection via single-cell RNA sequencing.Journal of virology · 2026Article
- Smartwatch-derived versus self-reported outcomes of physiological recovery after COVID-19, influenza, and group A streptococcus: a 2-year prospective cohort study.The Lancet. Digital health · 2026Article
- Molecular Roadmap of COVID-19: From Viral Entry to Therapeutic Targets.Chemistry & biodiversity · 2026Review
- Magnitude of SARS-CoV-2 Antibody Production and Its Relationship with Autoantibody Formation.Infectious diseases & clinical microbiology · 2025Article
- Impaired antibody responses to heterologous ChAdOx1 nCoV-19 and BNT162b2 vaccination in individuals with type 2 diabetes.Scientific reports · 2025Article
- Changes in peripheral blood mononuclear cell electrical properties in response to viral exposure and vaccination.Scientific reports · 2025Article
- Targeting heptad repeats and fusion peptide: nanoparticle vaccine elicits mucosal immune response against SARS-CoV-2 variants.Journal of nanobiotechnology · 2025Article
- Celluloepidemiology-A paradigm for quantifying infectious disease dynamics on a population level.Science advances · 2025Article
- A parainfluenza virus 5 (PIV5)-vectored intranasal SARS-CoV-2 vaccine (CVXGA1) elicits protective and long-lasting immunity in nonhuman primates.Journal of virology · 2025Article
- Multi-Antigen Viral-Vectored Vaccine Protects Against SARS-CoV-2 and Variants in a Lethal hACE2 Transgenic Mouse Model.Vaccines · 2025Article
- Sequences in the Cytoplasmic Tail Contribute to the Intracellular Trafficking and the Cell Surface Localization of SARS-CoV-2 Spike Protein.Biomolecules · 2025Review
- A SARS-CoV-2 vaccine on an NIR-II/SWIR emitting nanoparticle platform.Science advances · 2025Article
- Neutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough.European journal of medical research · 2025Article
624 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization has declared SARS-CoV-2 virus outbreak a worldwide pandemic. However, there is very limited understanding on the immune responses, especially adaptive immune responses to SARS-CoV-2 infection. Here, we collected blood from COVID-19 patients who have recently become virus-free, and therefore were discharged, and detected SARS-CoV-2-specific humoral and cellular immunity in eight newly discharged patients. Follow-up analysis on another cohort of six patients 2 weeks post discharge also revealed high titers of immunoglobulin G (IgG) antibodies. In all 14 patients tested, 13 displayed serum-neutralizing activities in a pseudotype entry assay. Notably, there was a strong correlation between neutralization antibody titers and the numbers of virus-specific T cells. Our work provides a basis for further analysis of protective immunity to SARS-CoV-2, and understanding the pathogenesis of COVID-19, especially in the severe cases. It also has implications in developing an effective vaccine to SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.